Merck & Co Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (96)

Latest Posts

About This Stock More About This Stock
Q4 Earnings Faring Well For Pharma ETFs
Article By: Sweta Killa
Monday, February 6, 2017 12:51 PM EST
The Q4 earnings season is faring better than the last few years with not only earnings growth on track to reach the highest level in two years but also total earnings set to create a new quarterly record.
In this article: MRK, PJP, IHE, XPH, PPH Also: JNJ, BMY, LLY, PFE
Read
Merck: Analyzing 2016 Performance & Outlook For 2017
Article By: SureDividend
Saturday, February 4, 2017 4:32 PM EST
Overall, Merck performed well in 2016. The company is growing sales and earnings, even in a difficult environment. And, Merck’s investments in R&D are clearing the way for future growth.
In this article: MRK Also: ABT, JNJ
Read
Déjà Vu
Article By: Marvin R Clark
Friday, February 3, 2017 12:30 AM EST
The number of Americans who applied for unemployment benefits at the end of January fell by 14,000 to 246,000, an extremely low level that might foreshadow another solid employment report tomorrow.
In this article: DB, M, MJN, MRK, RL, SNE, XOM, AMZN, FB, RBGLY, GOOGL
Read
Sirius XM Holdings Inc., Merck & Co., Inc. Post Solid Fourth Quarter Results
Article By: ValueWalk
Thursday, February 2, 2017 10:07 AM EST
Sirius XM reported 4 cents per share on $1.3 billion in revenue. Merck reported adjusted earnings of 89 cents per share, which was in line with the consensus estimate, on $10.12 billion in revenue
In this article: MRK, SIRI
Read
Merck & Co., Inc. Reports Tepid Results Due To Multiple Patent Expirations Of Key Medications
Article By: Lorimer Wilson
Thursday, February 2, 2017 10:00 AM EST
Merck & Co., Inc. early Thursday posted mixed fourth-quarter earnings and provided a tepid outlook, as it suffers through multiple patent expirations of key medications.
In this article: MRK
Read

PARTNER HEADLINES

Latest Tweets for $MRK

No tweets yet!